Evaluation of the Ability of Immune Humanized Mice to Demonstrate CD20‐Specific Cytotoxicity Induced by Ofatumumab

Evaluation of the Ability of Immune Humanized Mice to Demonstrate CD20‐Specific Cytotoxicity Induced by Ofatumumab

CD20 monoclonal antibodies are well‐established therapeutics for the treatment of B‐cell malignancies. Several mechanisms of target cell killing occur from anti‐CD20 therapy, including complement‐dependent cytotoxicity (CDC) cell lysis and antibody‐dependent cell‐mediated cytotoxicity. Human Fc rece...

Full description

Bibliographic Details
Main Authors:	Kenrick M. Semple, Carlos M. Gonzaléz, Melissa Zarr, José R. Austin, Vikram Patel, Kristina E. Howard
Format:	Article
Language:	English
Published:	Wiley 2019-05-01
Series:	Clinical and Translational Science
Online Access:	https://doi.org/10.1111/cts.12613

Similar Items

Ofatumumab: a novel monoclonal anti-CD20 antibody
by: Thomas S Lin
Published: (2010-05-01)

Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab
by: Despoina Florou, et al.
Published: (2020-10-01)

Role of ofatumumab in treatment of chronic lymphocytic leukemia
by: Veliz M, et al.
Published: (2011-05-01)

Refractory pemphigus vulgaris successfully treated with ofatumumab
by: Daniel M. Klufas, MD, et al.
Published: (2020-08-01)

The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia
by: Chadi Nabhan, et al.
Published: (2011-01-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
by: Halil Önder
Published: (2019-06-01)

New developments in the management of chronic lymphocytic leukemia: role of ofatumumab
by: Laurenti L, et al.
Published: (2016-01-01)

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia
by: Frustaci AM, et al.
Published: (2015-09-01)

The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies
by: Jorge Castillo, et al.
Published: (2010-02-01)

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
by: Emilia Quattrocchi, et al.
Published: (2016-01-01)

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
by: AlDallal SM
Published: (2017-07-01)

A Systematic Review of Efficacy and Safety of Ofatumumab Therapy in Children With Difficult-to-treat Nephrotic Syndrome
by: Yalda Ravanshad, et al.
Published: (2020-10-01)

Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
by: M Hoyle, et al.
Published: (2011-05-01)

P06 OFATUMUMAB FOR B CELL DEPLETION THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO ARE INTOLERANT OF RITUXIMAB
by: S. McAdoo, et al.
Published: (2016-11-01)

Pagetoid reticulosis positive for cytotoxic CD20 and CD30: A case report
by: Shufei Wei, et al.
Published: (2019-01-01)

Generation and Application of Antigen-Specific Induced Regulatory T cells in Allogeneic Bone Marrow Transplantation
by: Semple, Kenrick
Published: (2011)

The Selection of Aptamers to CD20 and Their Application as Inhibitors of Complement Dependent Cytotoxicity
by: Al-Youssef, Nadia
Published: (2015)

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia
by: Anthony J. Hatswell, et al.
Published: (2017-05-01)

Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ
by: Linda Lei, et al.
Published: (2018-09-01)

Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys
by: Diethilde Theil, et al.
Published: (2019-06-01)

Cytotoxic CD4 T Cells in Antiviral Immunity
by: Nikki B. Marshall, et al.
Published: (2011-01-01)

Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin – Prelimary results
by: Ewa Wąsik-Szczepanek, et al.
Published: (2018-03-01)

A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response.
by: Lifeng Wang, et al.
Published: (2012-01-01)

Demonstrating NISQ era challenges in algorithm design on IBM’s 20 qubit quantum computer
by: Daniel Koch, et al.
Published: (2020-09-01)

COPD monocytes demonstrate impaired migratory ability
by: Arjun K Ravi, et al.
Published: (2017-05-01)

30/20 GHz Demonstration System for Improving Orbit Utilization
by: Holmes, W. M., Jr.
Published: (1980)

Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia
by: Reslan, Lina
Published: (2010)

CD56 in the Immune System: More Than a Marker for Cytotoxicity?
by: Heleen H. Van Acker, et al.
Published: (2017-07-01)

Menthol-enhanced cytotoxicity of cigarette smoke demonstrated in two bioassay models
by: Atsuko Noriyasu, et al.
Published: (2013-08-01)

Direct and Indirect endocrine-mediated suppression of human endometrial CD8+T cell cytotoxicity
by: Z. Shen, et al.
Published: (2021-01-01)

Streblus asper attenuates alloxan-induced diabetes in rats and demonstrates antioxidant and cytotoxic effects
by: M. Oliur Rahman, et al.
Published: (2021-01-01)

Defects in the acquisition of tumor-killing capability of CD8+ cytotoxic T cells in streptozotocin-induced diabetic mice.
by: Shu-Ching Chen, et al.
Published: (2014-01-01)

CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I
by: Margaret A. Lindorfer, et al.
Published: (2013-11-01)

Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines <it>in vitro </it>and in <it>scid </it>mice
by: Jin Fang, et al.
Published: (2005-08-01)

CD8+ T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity
by: Roman V. Uzhachenko, et al.
Published: (2019-08-01)

CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential
by: Vanaja Konduri, et al.
Published: (2021-02-01)

Anti-CD20 therapy and pauci-immune crescentic glomerulonephritis
by: Kai-Hsiang Shu, et al.
Published: (2017-04-01)

Th17 Cell Enhances CD8 T-Cell Cytotoxicity via IL-21 Production in Emphysema Mice
by: Min-Chao Duan, et al.
Published: (2012-01-01)

The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans.
by: Karin Loser, et al.
Published: (2010-01-01)

CD56 regulates human NK cell cytotoxicity through Pyk2
by: Justin T Gunesch, et al.
Published: (2020-06-01)